Thomas Andrew Crockett - Nov 17, 2023 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CEO, Director
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Nov 17, 2023
Transactions value $
-$121,851
Form type
4
Date filed
11/21/2023, 04:30 PM
Previous filing
Nov 1, 2023
Next filing
Dec 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +33.6K +24.2% 172K Nov 17, 2023 Direct F1
transaction KALV Common Stock Sale -$122K -14.8K -8.59% $8.23 158K Nov 20, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -6.95K -11.11% $0.00 55.6K Nov 17, 2023 Common Stock 6.95K Direct F1, F3
transaction KALV Restricted Stock Unit Options Exercise $0 -5.81K -9.09% $0.00 58.1K Nov 17, 2023 Common Stock 5.81K Direct F1, F4
transaction KALV Performance Stock Unit Options Exercise $0 -20.8K -100% $0.00* 0 Nov 17, 2023 Common Stock 20.8K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and performance stock units ("PSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, for a period of three years, subject to continued service through each vesting date.
F4 1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.
F5 Each PSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F6 Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of November 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.